
Breast Cancer Prevention Pathway Map

Version 2024.10



Disclaimer: The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map.

In the situation where the reader is not a health care provider, the reader should always consult a healthcare provider if they have any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.



Line Guide

Target Population

People who are at a higher than average risk for breast cancer.

Pathway Map Considerations

- For more information about the evidence linking risk factors to breast cancer visit:
 - Cancer Risk Factors in Ontario: Healthy Weights, Healthy Eating and Active Living
 - Cancer Risk Factors in Ontario: Alcohol Report
- The OBSP provides high quality breast cancer screening free-of-charge in Ontario. The OBSP is informed by the guidelines developed by the Canadian Task Force on Preventative Health Care. The High Risk OBSP is based on a review of the evidence summarized in:
 - EBS 15-11 V3, Magnetic Resonance Imaging Screening of Women at High Risk for Breast Cancer. For more information on the OBSP refer to Ontario Breast Screening Program (OBSP).
- Primary care providers play an important role in the cancer journey and should be informed of relevant tests and consultations. Ongoing care with a primary care provider is assumed to be part of the pathway map. For patients who do not have a primary care provider, Health811 is a government resource that helps patients find a doctor or nurse practitioner.
- The OBSP has developed a conversation guide tool to support providers in having screening conversations with people ages 40-49. See <u>Breast Cancer Screening Resources for Healthcare Providers</u> for a tool to support breast cancer screening conversations with people ages 40-49.
- Throughout the pathway map, a shared decision-making model should be implemented to enable and encourage patients to play an active role in the management of their care. For more information see
 Person-Centered Care Guideline and EBS #19-2 Provider-Patient Communication.*
- Hyperlinks are used throughout the pathway map to provide information about relevant Ontario Health (Cancer Care Ontario) tools, resources, and guidance documents.
- The term health care provider, used throughout the pathway map, includes primary care providers and specialists, e.g. family doctors, nurse practitioners, and emergency physicians.
- For more information on wait times in Ontario, visit Wait Times.
- Clinical trials should be considered for all phases of the pathway map.
- MyCancerIQ is a tool available to providers to assess breast cancer risk.

Pathway Map Legend

Colour Guida

Colour Guide 311		ape duide Lille		Guide
Primary Care		Intervention		Required
Palliative Care	\Diamond	Decision or assessment point		Possible
Pathology		Patient (disease) characteristics		
Surgery		Consultation with specialist		
Radiation Oncology		Exit pathway		
Medical Oncology	\bigcirc or \bigcirc	Off page reference		
Radiology	R	Ref erral		
Multidisciplinary Cancer Conference (MCC)				
Genetics				
Psychosocial Oncology (PSO)				

Shana Guida

Pathway Map Disclaimer

This pathway map is a resource that provides an overview of the treatment that an individual in the Ontario cancer system may receive.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if they have any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

While care has been taken in the preparation of the information contained in the pathway map, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

Ontario Health (Cancer Care Ontario) and the pathway map's content providers (including the physicians who contributed to the information in the pathway map) shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the pathway map or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the pathway map does so at his or her own risk, and by using such information, agrees to indemnify Ontario Health (Cancer Care Ontario) and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the pathway map.

This pathway map may not reflect all the available scientific research and is not intended as an exhaustive resource. Ontario Health (Cancer Care Ontario) and its content providers assume no responsibility for omissions or incomplete information in this pathway map. It is possible that other relevant scientific findings may have been reported since completion of this pathway map. This pathway map may be superseded by an updated pathway map on the same topic.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if they have any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

Ontario Breast Screening Program (OBSP) Eligibility Criteria

Average Risk Screening

Women, Two Spirit, trans and nonbinary people are considered eligible for average risk screening if they are asymptomatic and meet all of the following criteria:

- Are 40-74 years of age*
- Have no personal history of breast cancer
- Have not had a mastectomy
- Have not had a screening mammogram within the last 11 months
- If transfeminine (i.e., assigned male at birth), has had at least five consecutive years of feminizing hormone use

For more information see: **Breast Screening Recommendations Summary**

* Participants over age 74 are encouraged to make a personal decision about breast cancer screening in consultation with their doctor or nurse practitioner and can continue to access screening through the program with a referral from their primary care provider. The OBSP does not send letters to people over age 74 about participating in the program. 2

People ages 40 to 49 should make an informed decision about whether breast cancer screening is right for them. The OBSP encourages people to have a conversation with their family doctor, nurse practitioner or Health811 navigator about their personal risk for breast cancer, the potential benefits and potential harms of breast cancer screening, and what matters most to them in taking care of their health.

People ages 40 to 49 have a lower chance of getting breast cancer than people ages 50 to 74. The balance of potential benefits to potential harms of breast cancer screening for people ages 40 to 49 may be different compared to people ages 50 to 74. For resources to support conversations with people ages 40 to 49 visit **Breast Cancer Screening Resources for Healthcare Providers**

High Risk Screening

Women, Two Spirit, trans and nonbinary people ages 30 to 69 can access screening through the High Risk OBSP if they have a referral from their primary care provider, a valid Ontario Health Insurance Plan number, no breast cancer symptoms and meet criteria listed in Category A or B (see below).

Category A – Eligible for direct entry into the High Risk OBSP based on personal and family history. To fall under this category, at least one of the following criteria must be met:

- Known carrier of a pathogenic or likely pathogenic gene variant (e.g., BRCA1, BRCA2, TP53, PALB2) that increases their risk for breast cancer
- Have not had genetic testing, but have had genetic counselling because they are a first-degree relative of a carrier of a pathogenic or likely pathogenic variant (e.g., BRCA1, BRCA2, TP53, PALB2) that increases their risk for breast cancer
- Previously assessed by a genetics clinic (using the IBIS or CanRisk risk assessment tools) as having a 25% or greater lifetime risk for breast cancer based on personal and family history
- Have had radiation therapy to the chest to treat another cancer (e.g., Hodgkin lymphoma) before age 30 and at least eight years ago

Category B – Genetic assessment required (i.e., counselling and/or testing) to determine eligibility for the High Risk OBSP. To fall under this category, at least one of the following criteria must be met:

- An identified pathogenic or likely pathogenic gene variant that is associated with breast cancer risk (e.g., BRCA1, BRCA2, TP53, PALB2) in a close blood relative
- A personal or family history of a cancer suggestive of a hereditary breast cancer syndrome

Note: People with a personal history of breast cancer may access screening through the High Risk OBSP if they meet program eligibility criteria.

The High Risk OBSP does not accept new participants over age 70. However, when participants already in the High Risk OBSP turn 70, the program will continue to screen them with just mammography every year until they are age 74.

Participants over age 74 are encouraged to make a personal decision about breast cancer screening in consultation with their doctor or nurse practitioner and can continue to be screened with just mammography through the High Risk OBSP with a referral from their primary care provider. The High Risk OBSP does not send letters to people over age 74 about participating in the program.

For more information see: Breast Cancer Screening for People at High Risk and OBSP Requisition for High Risk Screening.

Assessment of Breast Cancer Risk and Prevention Guidance

Version 2024.04 Page 4 of 4

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if they have any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

Health behaviour interventions (e.g., exercise, nutrition) should be considered for all individuals of any risk category. Preventative treatment may include From one or more of the following: Screening/ Proceed Diagnosis From the High Risk Bilateral Salpingo-Oophorectomy^{2,3} to Screening/ **Appropriate** Pathway OBSP If age ≥35 years and carrier of a Eligible Diagnosis Healthcare Map pathogenic variant of BRCA 1/2 Carrier of Pathway Map Provider (Page 7) pathogenic (Page 8) Bilateral Mastectomy e.g. medical Proceed variant in BRCA Meets criteria for referral (+/- reconstruction) oncologist, to Screening 1/2 to High Risk OBSP. surgeon, Chemoprevention⁴ Diagnosis Discuss gynecologist) Pathway Map Considered if age ≥35 years **High Risk OBSP** appropriate breast (Page 4) Requisition screening and Individualized cancer genetics risk reassess High Risk management consultation. Carrier of a Individualized OBSP eligibility pathogenic variant cancer genetics risk management in another gene on **Refer to Genetics** the panel consultation. Family history of **Program for formal** Primary care Follow-up relevant cancer but not assessment of review of breast Preventative treatment may Not Eligible managed eligible for High Risk hereditary breast Appropriate cancer risk. include one or more of the (e.g., age, Outcome OBSP screening cancer risk and genetic Results Healthcare ≥25% lifetime risk (e.g. family, clinical following: bilateral primary (e.g., strong family test when eligible Provider of breast cancer1 and history, My Cancer **Bilateral Mastectomy** mastectomy) history & 18 to 29 **Hereditary Cancer** e.g. medical not a carrier of a IQ) (+/- reconstruction) provider years of age) oncologist, **Testing Eligibility** pathogenic variant Criteria surgeon, Chemoprevention⁶ gynecologist) Considered if age ≥35 years <25% lifetime risk Proceed of breast cancer1 to Screening/ Average lifetime risk Eligible Diagnosis of breast cancer1 (no **Pathway Map** additional risk factors) (Page 6) Discuss appropriate breast screening and Increased risk of breast Follow-up **OBSP** average risk cancer for non-genetic reasons Chemoprevention4 managed **Appropriate** eligibility (e.g. high risk lifestyle, alcohol, Considered if age ≥ 35 years; Healthcare Not eligible obesity, age, previous childhood assessment for From primary Provider cancer) R appropriateness using risk care Screening/ (e.g. primary assessment model and Diagnosis provider Confirmed high-risk care, medical consideration of specific risk Pathway Map benign lesion oncologist) factors (Page 10)

Disclaimer: If you need this document in accessible format, please contact 1-877-280-8538, TTY 1-800-855-0511, info@ontariohealth.ca and OH-CCO_CIDAPInfo@ontariohealth.ca. Available in English only due to its technical nature and limited target audience. A French version can be made available upon request. For questions, please email info@ontariohealth.ca

Disponible en anglais seulement en raison de sa nature technique et de son public cible limité. Une version en français peut être fournie sur demande. Pour toute question, veuillez envoyer un courriel à <u>info@ontariohealth.ca</u>

¹Lifetime risk of breast cancer should be based on personal and family history and must have been assessed using IBIS or CANRISK risk assessment tools, at a genetics clinic. For more information on these tools visit http://www.ems-trials.org/riskevaluator/ for IBIS and https://www.canrisk.org for CANRISK.

² Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2021 Jan 6;19(1):77–102.

³ For information on the examination of bilateral salpingo-oophorectomy specimens visit the CAP checklists at www.cap.org

⁴Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, et al. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of clinical oncology. 2019;37(33):3152–65. Available from: https://edoc.unibas.ch/72124/.